Lapatinib and Bortezomib in Patients With Advanced Malignancies

Inclusion Criteria: * Histologically proven malignant solid tumor with measurable disease * Progression on, or intolerance of, or ineligibility for all standard therapies * Biopsy accessible tumor deposits * LVEF \>/= institutional normal * Corrected QT interval less than 500 milliseconds by EKG * ECOG performance status 0-2 * Subjects with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intercranial disease and have not had treatment with steroids within 1 week of enrollment. * Adequate hepatic, bone marrow, and renal function * Partial thromboplastin time must be \</= 1.5 x upper limit of institution's normal range and INR \< 1.5. Subjects on anticoagulants will be permitted to enroll as long as the INR is in the acceptable therapeutic range. * Life expectancy \> 12 weeks * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months. * Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the informed consent form. Exclusion Criteria: * Patients with lymphomas * CNS metastases which do not meet the criteria outlines in the inclusion criteria * Peripheral neuropathy \>/= Grade 2 at baseline or peripheral neuropathy \>/= Grade 1 with neuropathic pain * Active severe infection or known chronic infection with HIV or hepatitis B virus * Cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months * Life-threatening visceral disease or other severe concurrent disease * Women who are pregnant or breastfeeding * Anticipated patient survival under 3 months * Concurrent use of known CYP 3A4 inhibiting or activating medications